Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1919P - Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Kate Newbold

Citation

Annals of Oncology (2020) 31 (suppl_4): S1026-S1033. 10.1016/annonc/annonc293

Authors

K. Newbold1, P. Schoeffski2, B. Hasan3, L.D. Locati4, Y. Godbert5, C. de la Fouchardiere6, L. Bastholt7, M. Fassnacht8, N. Reed9, Y. Lalami10, C. Chougnet11, C. Schvartz12, E. Kapiteijn13, M.J. Schlumberger14, W. Sents3, N. Sauve15, S. Leboulleux16

Author affiliations

  • 1 Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 2 Medical Oncology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 3 Eortc, EORTC, 1200 - Brussels/BE
  • 4 Head And Neck Cancer Medical Oncology Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 5 Nuclear Medicine, Institut Bergonie, 33076 - Bordeaux/FR
  • 6 Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR
  • 7 Dept Of Oncology, Odense University Hospital - Children Center, 5000 - Odense/DK
  • 8 Department Of Internal Medicine I - Division Of Endocrinology, University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), 97080 - Wuerzburg/DE
  • 9 Medical Oncology Department, Gartavel General Hospital, G12 0YN - Glasgow/GB
  • 10 Medical Oncology Dept., Institute Jules Bordet, 1000 - Brussels/BE
  • 11 Nuclear Medicine, Hôpital Saint Louis AP-HP, 75010 - Paris/FR
  • 12 Nuclear Medicine, Institut Godinot, 51056 - Reims/FR
  • 13 Medical Oncology Dept., Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 14 Nuclear Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 15 Eortc, EORTC, 12000 - Brussels/BE
  • 16 Medecine Nuclear And Endocrine Oncology, Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Abstract 1919P

Background

Patients with progressive advanced medullary thyroid cancer (MTC) after vandetanib and/or cabozantinib had limited treatment options at the time the trial was launched. Nintedanib is a triple angiogenesis inhibitor. The aim of this prospective randomized double-blind phase II study was to evaluate nintedanib in progressing MTC pts after 1 or 2 lines of prior TKI treatment.

Methods

Pts with documented RECIST v1.1 progression on a prior TKI treatment were randomized to nintedanib or placebo (2:1 ratio). The primary endpoint was progression free survival (PFS) using local RECIST v1.1. With a 1-sided alpha 10%, the study was powered at 90% level to detect a Hazard Ratio (HR) of 0.6 in PFS. The cohort was stopped due to slow accrual with 32/67 pts enrolled without reaching the targeted statistical power. Treatment effects were estimated using the Cox model and presented with their 95% confidence interval (CI) without p-values.

Results

Thirty-two pts patients (med age: 56.9 yrs; 75% male), with progressing MTC were enrolled; 31 were randomized to receive nintedanib (22 pts) or placebo (9 pts) (intention to treat); 20 pts (15 nintedanib; 5 placebo met all inclusion criteria (per protocol)). In the per-protocol population, median PFS was 3.9 (3.0, 7.1) months under placebo and 7.0 (1.8, 8.8) months under nintedanib (HR=0.49; 95% CI 0.16-1.53). The best overall response was stable disease in 9 (60%) pts under nintedanib and 4 (80%) under placebo. Median overall survival was 12.3 months under nintedanib (median follow-up 48.4 months) and 16.4 months under placebo (median follow-up 19.7 months). In the intention to treat population, median PFS was 3.6 (1.8, 5.5) months under placebo and 6.4 (1.9, 8.7) months under nintedanib (HR=0.40; 95% CI: 0.17-0.99) At least one Grade 3-4 adverse event occurred in 13 (59%) pts under nintedanib and 3 (33%) under placebo. The most common AEs under nintedanib were diarrhea (18 %), nausea (9%) increase in gammaGT (18%) and lymphopenia (18%).

Conclusions

Due to a slow accrual the study was closed. Among pts included, nintedanib appears safe, yet no conclusion on efficacy could be drawn due to the low power of the study.

Clinical trial identification

NCT01788982.

Editorial acknowledgement

Legal entity responsible for the study

EORTC.

Funding

Boehringer Ingelheim.

Disclosure

K. Newbold: Honoraria (self): Eisai. P. Schoeffski: Honoraria (self), Advisory/Consultancy: Deciphera; Honoraria (self), Advisory/Consultancy: Blueprint Medicines; Honoraria (self), Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy: Plexxikon; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy: Loxo; Advisory/Consultancy: Lilly; Advisory/Consultancy: Ellipses Pharma; Advisory/Consultancy: Merck; Advisory/Consultancy: Servier; Advisory/Consultancy: Genmab; Advisory/Consultancy: Adaptimmune; Advisory/Consultancy: Intellisphere; Advisory/Consultancy: Transgene; Advisory/Consultancy: Exelixis; Research grant/Funding (institution): CoBioRes NV; Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (institution): PharmaMar; Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Ipsen. L.D. Locati: Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self): MSD; Honoraria (self), Advisory/Consultancy: Merck Serono; Honoraria (self): Mc Cann Healthcare; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Biogen. C. de la Fouchardiere: Advisory/Consultancy, Travel/Accommodation/Expenses: Servier; Advisory/Consultancy: Bayer; Advisory/Consultancy: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Pierre Fabre Oncology; Advisory/Consultancy: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses: Eisai; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: BMS. L. Bastholt: Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self), Advisory/Consultancy: Sanofi-Genzyme; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Speaker Bureau/Expert testimony: Roche; Honoraria (self), Speaker Bureau/Expert testimony: Merck MSD. E. Kapiteijn: Honoraria (institution): Eisai; Honoraria (institution): Bayer; Honoraria (institution): Sanofi Genzyme. S. Leboulleux: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Eisai; Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Research grant/Funding (institution): Sanofi Genzyme; Research grant/Funding (institution): Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings